Patients should not use alli (orlistat 60 mg) if they have had an organ transplant or if they are taking medicine to reduce organ rejection.
alli™ (orlistat 60 mg) has low potential for misuse and drug interactions because of the mechanism of action and minimal systemic absorption. The only known drug interactions can occur with cyclosporine and warfarin (blood-thinning medicine).
Patients should not use alli (orlistat 60 mg) if taking cyclosporine; alli (orlistat 60 mg) can reduce levels of cyclosporine in the blood.
Patients on warfarin should talk with their doctor before taking alli (orlistat 60 mg) ; they will need to be monitored closely for changes in coagulation parameters and have their blood tested regularly, which is standard for any individual taking warfarin who is considering starting a new concomitant drug.
Patients taking medicine for thyroid disease should talk to their doctor before taking alli (orlistat 60 mg) .
alli (orlistat 60 mg) does not negatively interfere with diabetes medication; In fact, a clinical trial has demonstrated that patients taking orlistat have been able to reduce or discontinue their diabetes medicine.1
No clinically relevant drug interactions were seen when alli (orlistat 60 mg) was taken in combination with weight loss drugs, such as phentermine or sibutramine.2
References
1 Miles J, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;25:1123-1128.
2 Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. Amer Coll Clin Pharmacol. 2002;42:1011-1019.
Last reviewed on RxList: 6/20/2007
This monograph has been modified to include the generic and brand name in many instances.